Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
Cosmos Health (NASDAQ:COSM) has entered an exclusive agreement with Virax Biolabs to distribute mpox virus real-time PCR detection kits across India, a market with over 1.4 billion people. This expansion follows a recent second reported case of mpox in India on September 18, 2024. The agreement positions Cosmos Health to support India's efforts in identifying and managing mpox cases, contributing to public health initiatives.
This move comes after the WHO declared a global public health emergency on August 14, 2024, due to rising mpox cases in Africa and its spread to Europe and Asia. The agreement extends Cosmos Health's partnership with Virax beyond Europe, following a recent exclusive distribution agreement for the Gulf region.
Cosmos Health (NASDAQ:COSM) ha stipulato un accordo esclusivo con Virax Biolabs per distribuire kit di rilevamento PCR in tempo reale per il virus mpox in India, un mercato con oltre 1,4 miliardi di persone. Questa espansione segue un recente secondo caso riportato di mpox in India il 18 settembre 2024. L'accordo posiziona Cosmos Health per supportare gli sforzi dell'India nell'identificazione e gestione dei casi di mpox, contribuendo alle iniziative di salute pubblica.
Questa mossa arriva dopo che la OMS ha dichiarato un'emergenza sanitaria pubblica globale il 14 agosto 2024, a causa dell'aumento dei casi di mpox in Africa e della sua diffusione in Europa e Asia. L'accordo estende la partnership di Cosmos Health con Virax oltre l'Europa, a seguito di un recente accordo di distribuzione esclusiva per la regione del Golfo.
Cosmos Health (NASDAQ:COSM) ha firmado un acuerdo exclusivo con Virax Biolabs para distribuir kits de detección PCR en tiempo real del virus mpox en India, un mercado de más de 1.4 mil millones de personas. Esta expansión sigue a un reciente segundo caso reportado de mpox en India el 18 de septiembre de 2024. El acuerdo sitúa a Cosmos Health para apoyar los esfuerzos de India en la identificación y gestión de casos de mpox, contribuyendo a las iniciativas de salud pública.
Este movimiento se produce después de que la OMS declarara una emergencia de salud pública global el 14 de agosto de 2024, debido al aumento de casos de mpox en África y su propagación a Europa y Asia. El acuerdo extiende la asociación de Cosmos Health con Virax más allá de Europa, tras un reciente acuerdo de distribución exclusiva para la región del Golfo.
코스모스 헬스(NASDAQ:COSM)는 비락스 바이오랩스와 독점 계약을 체결하고 인도 전역에 mpox 바이러스 실시간 PCR 탐지 키트를 배포하게 되었습니다. 이는 14억 명 이상의 인구를 가진 시장입니다. 이 확장은 2024년 9월 18일 인도에서 보고된 두 번째 mpox 사례 이후 이루어졌습니다. 이 계약은 코스모스 헬스가 mpox 사례를 식별하고 관리하는 인도의 노력을 지원하여 공공 건강 이니셔티브에 기여하는 위치를 설정합니다.
이러한 움직임은 WHO가 2024년 8월 14일 전 세계 공공 건강 비상 사태를 선언한 것에 따른 것으로, 아프리카에서의 mpox 사례 증가와 유럽 및 아시아로의 확산이 원인입니다. 이 계약은 코스모스 헬스가 비락스와의 파트너십을 유럽을 넘어 확장하며, 최근 걸프 지역에 대한 독점 배급 계약 이후 이루어진 것입니다.
Cosmos Health (NASDAQ:COSM) a conclu un accord exclusif avec Virax Biolabs pour distribuer des kits de détection PCR en temps réel du virus mpox à travers l'Inde, un marché de plus de 1,4 milliard de personnes. Cette expansion fait suite à un récent deuxième cas signalé de mpox en Inde le 18 septembre 2024. L'accord positionne Cosmos Health pour soutenir les efforts de l'Inde dans l'identification et la gestion des cas de mpox, contribuant ainsi aux initiatives de santé publique.
Ce mouvement intervient après que la OMS a déclaré une urgence sanitaire mondiale le 14 août 2024, en raison de l'augmentation des cas de mpox en Afrique et de sa propagation en Europe et en Asie. L'accord prolonge le partenariat de Cosmos Health avec Virax au-delà de l'Europe, après un récent accord de distribution exclusif pour la région du Golfe.
Cosmos Health (NASDAQ:COSM) hat eine exklusive Vereinbarung mit Virax Biolabs über die Verteilung von mpox-Virus-Real-time-PCR-Detection-Kits in Indien, einem Markt mit über 1,4 Milliarden Menschen, getroffen. Diese Expansion folgt einem jüngsten zweiten gemeldeten Fall von mpox in Indien am 18. September 2024. Die Vereinbarung positioniert Cosmos Health, um Indiens Bemühungen zur Identifizierung und Handhabung von mpox-Fällen zu unterstützen und zu öffentlichen Gesundheitsinitiativen beizutragen.
Dieser Schritt erfolgt, nachdem die WHO am 14. August 2024 einen globalen Gesundheitsnotstand ausgerufen hat, bedingt durch steigende mpox-Fälle in Afrika und deren Verbreitung nach Europa und Asien. Die Vereinbarung erweitert die Partnerschaft von Cosmos Health mit Virax über Europa hinaus, nach einer kürzlich geschlossenen exklusiven Vertriebsvereinbarung für die Golfregion.
- Exclusive distribution agreement for mpox PCR detection kits in India
- Expansion into a market with over 1.4 billion people
- Strategic positioning to support public health initiatives in India
- Extension of partnership with Virax Biolabs beyond Europe
- None.
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an exclusivity agreement with Virax Biolabs to distribute mpox (formerly monkeypox) virus real-time PCR detection kits across India.
With a population of over 1.4 billion, India is an important region where enhanced detection capabilities are needed. Following the second reported case of mpox on September 18, 2024, Cosmos Health is well-positioned to support the country's efforts in identifying and managing cases, contributing to ongoing public health initiatives.
On August 14, 2024, WHO Director-General Dr. Tedros Adhanom Ghebreyesus declared a global public health emergency due to the rising mpox cases in the Democratic Republic of the Congo and other African nations. Since then, mpox has spread beyond Africa, with confirmed cases in Europe and Asia, raising global concern.
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased to expand our strategic partnership with Virax well beyond Europe. Following our recent exclusive agreement to distribute detection kits throughout the Gulf region, we are now extending this collaboration to India, further strengthening our global presence."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc
View the original press release on accesswire.com
FAQ
What is the new distribution agreement Cosmos Health (COSM) has entered?
When was the second case of mpox reported in India, according to the Cosmos Health (COSM) press release?
When did the WHO declare a global public health emergency due to mpox?
What other region did Cosmos Health (COSM) recently secure an exclusive distribution agreement for mpox detection kits?
